

THE NOMINATION COMMITTEE'S PROPOSALS FOR THE AGM 2019

The Nomination Committee for the AGM 2019 comprises the following members: Per Lönn, representing PharmaResearch Products Ltd, (Chairman of the Nomination Committee), David Sundin, representing Midroc New Technology AB, Graham Fagg, representing Rosetta Capital IV S.à r.l. and Göran Pettersson, Chairman of the Board in Promore Pharma AB (publ).

The Nomination Committee's members represent approximately 88 per cent of the shares and votes in Promore Pharma AB (publ).

The Nomination Committee presents the following proposals for the AGM 2019.

Election of Chair of the meeting

The Nomination Committee proposes that Anders Björnsson, Advokaterna Liman & Partners, be elected to chair the meeting.

Determination of the number of directors, alternate directors and auditor and alternate auditor

The Nomination Committee proposes that the Board shall be composed of six directors, with no alternates, for the period until the next AGM. The Nomination Committee proposes that the company will have one auditor and no alternate.

Determination of the fees for the directors and for the auditor

The Nomination Committee proposes that the fees remain unchanged with SEK 250,000 for the Chairman of the Board, SEK 150,000 each for independent directors and SEK 100,000 each for directors employed by principal shareholders of the company.

Fees will be paid to the auditor in accordance with approved invoices.

Election of directors, Chairman of the Board and auditor, and, when applicable, alternate directors and an alternate auditor

The Nomination Committee proposes re-election of Marianne Dicander Alexandersson, Torsten Goesch, Satyendra Kumar, Göran Linder and Göran Pettersson and proposes Kerstin Vallinder Strinnholm as a new director of the Board.

It is proposed that Göran Pettersson be re-elected Chairman of the Board.

Information about the proposed directors is available on the company's website:

www.promorepharma.com.

The Nomination Committee proposes that the registered audit company Finnhammars Revisionsbyrå AB be appointed auditor. Finnhammars Revisionsbyrå AB has given notice that Ola Spinnars will be the person appointed to have main responsibility for the audit.

REASONED STATEMENT BY THE NOMINATION COMMITTEE

As a basis for its proposals the Nomination Committee has carried out an evaluation of the present Board's work. The Nomination Committee has had nine recorded meetings and had contact by phone and e-mail on a number of occasions between meetings.

In this evaluation the Nomination Committee has found that the present Board's work was satisfying and well-functioning, that the attendance at Board meetings has been very high, and that the Chairman of the Board has presided the work efficiently.

In the opinion of the Nomination Committee's the proposed Board has a relevant composition, given the company's business and development stage, and that the proposed directors possess an extensive competence with solid industrial as well as financial knowledge with an international experience.

Although the Nomination Committee considers the Board's composition relevant, the Nomination Committee will, when recruiting candidates in the future, continue the search for suitable candidates representing both genders.

Solna April 2019

Nomination Committee for Promore Pharma AB (publ)